Multiple Sclerosis Market Size | COVID-19 Impact Analysis | Forecast to 2027
The global multiple sclerosis market is anticipated to grow at a CAGR of around 2.5% during the forecast period (2021-2027). Multiple sclerosis is a neurological disorder characterized by loss of the myelin sheath. The rising prevalence of MS globally is one of the major factors driving the growth of the market. Many market players such as Bayer AG, Merck KGaA, Mylan N.V., Novartis AG, Pfizer Inc., are contributing towards the growth of the market by generating effective drugs and treatments for multiple sclerosis therapies. Moreover, the US FDA approvals to the drugs for the treatment of MS is the pivotal factor boosting the market growth. For instance, in March 2021, The US Food and Drug Administration (FDA) has approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s (JNJ) PONVORY (ponesimod) for treating adults with relapsing forms of multiple sclerosis. Besides, in April 2020, Merck KGaA announced that it has received approval from the US FDA for its Mavenclad an oral dosage for the treatment of multiple sclerosis. Additionally, the mergers and acquisition among major players to expand their business footprints globally and products offerings in multiple sclerosis treatments are further expected to boost the market growth. For instance, in February 2021, Jazz Pharmaceuticals plc announced the acquisition of GW Pharmaceuticals plc through a definitive agreement. The acquisition was done for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. Through this acquisition, both the companies as combined will expand their commercial and operational footprint in the field of neuroscience globally.
To Request a Sample of our Report on Multiple Sclerosis Market: https://www.omrglobal.com/request-sample/multiple-sclerosis-market
The rising awareness programs by the government associations for
multiple sclerosis treatments playing an important role in the market
development. For instance, in May 2021, Celgene Corporation and the Multiple
Sclerosis Association of America (MSAA) announced the launch of a new campaign,
MS MindShift, a national initiative that provides a new perspective on multiple
sclerosis. The campaign aims to educate about the critical role the brain plays
in the disease and what people living with multiple sclerosis can do to keep
their brain as healthy as possible, for as long as possible.
·
The
market number available for – 2020-2027
·
Base
year- 2020
·
Forecast
period- 2021-2027
Segment
Covered-
·
By
Types
·
By Diagnostics
Technologies
·
By Mode
of Administration
·
By Drug
Class
Regions
Covered-
·
North
America
·
Europe
·
Asia-Pacific
·
Rest of
the World
·
Competitive
Landscape- AbbVie Inc., Bayer AG, Merck KGaA, Mylan N.V., Novartis AG, Pfizer
Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Teva Pharmaceutical Industries
Ltd., among Others.
Key questions
addressed by the report
·
What is
the market growth rate?
·
Which
segment and region dominate the market in the base year?
·
Which
segment and region will project the fastest growth in the market?
How COVID-19
impacted the market?
o Deviation from the pre-COVID-19
forecast
o Most affected region and segment
·
Who is
the leader in the market?
·
How
players are addressing challenges to sustain growth?
· Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A
full Report of Multiple Sclerosis Market is Available at: https://www.omrglobal.com/industry-reports/multiple-sclerosis-market
·
Primary
Progressive MS
·
Progressive
Relapsing MS
·
Relapsing
Remitting MS
·
Secondary
Progressive MS
By
Diagnostics Technologies
·
MRI
·
Evoked
Potential Test
·
Spinal
Fluid Test
·
Others
By Mode of
Administration
·
Injectable
Agents
·
Oral
Agents
·
Intravenous
Therapy
By Drug Class
·
Immunomodulators
·
Immunosuppressant
Global
Multiple Sclerosis Market Report Segment by Region
·
United
States
·
Canada
Europe
·
UK
·
Germany
·
Italy
·
Spain
·
France
·
Rest of
Europe
Asia-Pacific
·
China
·
India
·
Japan
·
South
Korea
·
Rest of
Asia-Pacific
Rest of the
World
·
Latin
America
·
Middle
East & Africa
Company
Profiles
·
AbbVie
Inc.
·
AB
Science SA
·
Active Biotech
·
Acorda
Therapeutics, Inc.
·
Bayer
AG
·
Biogen
Inc.
·
BrainStorm
Cell Ltd.
·
CELGENE
CORPORATION
·
Forward
Pharma A/S
·
Genentech,
Inc
·
GW
Pharmaceuticals Plc
·
Johnson
& Johnson Services Inc.
·
Merck
KGaA
·
Medday
Pharmaceuticals GmbH
·
Mylan
N.V.
·
Novartis
AG
·
Pfizer
Inc.
·
F.
Hoffmann-La Roche Ltd.
·
Sanofi
S.A.
·
Teva
Pharmaceutical Industries Ltd.
·
TG
Therapeutics, Inc.
Reasons for Buying from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More
Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/multiple-sclerosis-market
About Orion
Market Research
Orion Market Research (OMR) is a market
research and consulting company known for its crisp and concise reports. The
company is equipped with an experienced team of analysts and consultants. OMR
offers quality syndicated research reports, customized research reports,
consulting and other research-based services.
For More Information, Visit Orion
Market Research
Media Contact:
Company Name: Orion Market
Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment